Skip to main content
. 2023 Jan 18;48(1):E23–E33. doi: 10.1503/jpn.220117

Table 2.

Demographic and clinical characteristics of both study groups at baseline

Characteristic Randomized sample
n = 60
CCA* sample
n = 47
Modified ITT sample
n = 43



Probiotic
n = 30
Placebo
n = 30
Group comparison Probiotic
n = 21
Placebo
n = 26
Group comparison Probiotic
n = 19
Placebo
n = 24
Group comparison
Sex, female, n (%) 20 (66.7) 16 (53.33) χ21 = 0.63, p = 0.43 14 (67) 13 (50) χ21 = 0.73, p = 0.49 14 (74) 12 (50) χ21 = 1.60, p = 0.21
Age, mean ± SD 38.03 ± 11.32 37.87 ± 10.32 W = 443, p = 0.92 39.43 ± 11.45 38.77 ± 10.32 W = 278, p = 0.92 39.21 ± 11.53 38.04 ± 10.24 W = 238.5, p = 0.81
BMI, mean ± SD 23.53 ± 3.82 25.20 ± 3.50 W = 334, p = 0.13 23.50 ± 3.67 24.88 ± 3.95 W = 207, p = 0.23 23.83 ± 3.66 25.13 ± 4.01 W = 177, p = 0.30
Smoking, n (%)
 ≥ 1/day 9 (30) 12 (40) χ24 = 3.21, p = 0.52 7 (33) 11 (42) χ21 = 0.27, p = 0.60 5 (26) 10 (42) χ21 = 0.87, p = 0.35
 NA 10 (33.3) 8 (26.7) 3 (14) 5 (19) 3 (16) 5 (21)
Hospitalization, n (%)
 1 10 (33) 13 (43) W = 274, p = 0.41 8 (38) 12 (46) W = 224.5, p = 0.45 7 (37) 12 (50) W = 210.5, p = 0.32
 2 4 (13) 5 (17) 4 (19) 5 (19) 4 (21) 4 (17)
 3 3 (10) 3 (10) 3 (14) 3 (12) 3 (16) 3 (13)
 4 0 (0) 1 (3) 0 (0) 1 (4) 0 (0) 1 (4)
 5 3 (10) 0 (0) 3 (14) 0 (0) 3 (16) 0 (0)
 ≥ 6 1 (3) 1 (3) 0 (0) 1 (4) 0 (0) 1 (4)
 NA 9 (30) 7 (23) 3 (14) 4 (15) 2 (11) 3 (13)
Education, n (%)
 Primary 9 (30) 6 (20) W = 423, p = 0.42 7 (33) 4 (15) W = 269.5, p = 0.88 6 (32) 4 (17) W = 237, p = 0.63
 Secondary 3 (10) 12 (40) 3 (14) 12 (46) 3 (16) 12 (50)
 Tertiary 16 (53) 9 (30) 11 (52) 9 (35) 10 (53) 7 (29)
 NA 2 (7) 3 (10) 0 (0) 1 (4) 0 (0) 0 (0)
Medication, DDD, mean ± SD
 Antidepressant equivalents NA NA NA 1.73 ± 1.30 1.79 ± 1.09 W = 253, p = 0.68 1.86 ± 1.30 1.82 ± 1.12 W = 227, p = 0.99
 Antipsychotics equivalents NA NA NA 0.30 ± 0.68 0.22 ± 0.30 W = 278, p = 0.92 0.33 ± 0.71 0.24 ± 0.31 W = 241, p = 0.76
Clinical measures, mean ± SD
 HAM-D 18.90 ± 4.7 16.7 ± 4.10 W = 552, p = 0.08 18.93 ± 4.78 16.5 ± 4.04 W = 363, p = 0.05 19.13 ± 4.89 16.5 ± 4.18 W = 311, p = 0.04
 BDI 22.5 ± 8.10 22.12 ± 9.90 W = 461.5, p = 0.69 22.38 ± 7.54 22.33 ± 10.17 W = 257.5, p = 0.96 21.53 ± 7.59 22.31 ± 9.94 W = 218.5, p = 0.96
 STAI1 42.32 ± 5.525 41.10 ± 6.53 W = 472.5, p = 0.42 49.75 ± 13.89 52.36 ± 10.40 W = 229.5, p = 0.65 49 ± 14.11 51.83 ± 10.61 W = 191, p = 0.68
 GSRS 30.21 ± 9.94 29.53 ± 12.06 W = 479, p = 0.51 28.52 ± 9.48 29.83 ± 12.45 W = 261, p = 0.98 28.16 ± 9.65 29.96 ± 12.79 W = 211.5, p = 0.87
Compliance, %, mean ± SD NA NA NA 83 ± 17.21 86 ± 11.72 W = 231, p = 0.76 87 ± 8.44 88 ± 8.17 W = 186, p = 0.84

BDI = Beck Depression Inventory; BMI = body mass index; CCA = complete case analysis; DDD = defined daily dose; GSRS = Gastrointestinal Symptom Rating Scale; HAM-D = Hamilton Rating Scale for Depression; ITT = intention to treat; NA = not applicable; SD = standard deviation; STAI1 = State–Trait Anxiety Inventory 1.

*

Referred to as ITT in Schaub et al.19

Also referred to as modified ITT in Schaub et al.19

Non-normally distributed, b square root–transformed.